Nkarta, Inc.

NASDAQ:NKTX

Biotechnology

Healthcare
$1.15 +3.41%

+$0.09 today

Market cap
$82.37M
Beta
0.90
P/E (TTM)
-2.0
EPS (TTM)
-$1.35
52W Low $1.63High $3.65

Volume 0.81M

Average 0.75M

NKTX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Nkarta, Inc.NASDAQ: NKTX

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$30.88M, compared with -$36.56M a year earlier. Trailing-twelve-month operating income was -$116.31M.

Context

  • Operating income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +5.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$30.88M+0.3% QoQ
Last fiscal yearDec 2025
-$121.21M+5.5% YoY
LTMMar 2026
-$116.31M+11.9% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.6%+100.0%+84.4 pp
1 year+5.5%+100.0%+94.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(121.21M) USD
Year-over-year change
+5.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How NKTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.9% is the 4th highest of 8, against a peer median of +6.5%.
NKTX Competitors
Operating Income for NKTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$37.58M USD+17.4%——
MOLNMolecular Partners AGLTM Mar 2026-CHF 61.98M CHF+2.1%——
FBRXForte Biosciences, Inc.LTM Mar 2026-$76.97M USD-71.3%——
PEPGPepGen Inc.LTM Mar 2026-$81.23M USD+25.7%——
NKTXNkarta, Inc.LTM Mar 2026-$116.31M USD+11.9%——
ALECAlector, Inc.LTM Mar 2026-$136.53M USD+6.5%—741.3%
FATEFate Therapeutics, Inc.LTM Mar 2026-$139.42M USD+30.5%—2207.5%
VORVor Biopharma Inc.LTM Mar 2026-$373.51M USD-205.8%——
Peer median (excluding NKTX) —+6.5%—1474.4%

Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue005.87M09.19M
Gross Profit00(5.87M)0(9.19M)
Gross Margin—————
Research & Development63.41M90.9M90.9M96.74M90.43M
Selling, General & Admin23.02M28.06M34.88M31.45M31.57M
Operating Expenses86.43M118.96M125.78M128.19M112.01M
Depreciation & Amortization1.76M2.64M5.87M9.15M9.19M
EBITDA(84.32M)(105.61M)(120.48M)(99.64M)(94.89M)
EBITDA Margin—————
Operating Income(86.43M)(118.96M)(131.65M)(128.19M)(121.21M)
Operating Margin—————
Interest Income370K5.59M14.11M19.32M15.49M
Interest Expense05.59M000
Other Income / Expenses354K5.12M14.15M19.4M17.12M
Income Before Tax(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Net Margin—————
EPS (Basic)(2.62)(2.61)(2.40)(1.60)(1.41)
EPS (Diluted)(2.62)(2.61)(2.40)(1.60)(1.41)
Weighted Avg Shares32.86M43.63M49.01M67.87M73.99M
Weighted Avg Shares (Diluted)32.86M43.63M49.01M67.87M73.99M

Nkarta, Inc.

NASDAQ:NKTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.